Last edition
News about "Ofer Haviv"
Evogene and Tel Aviv University Launch AI Drug Discovery Initiative
Evogene and Tel Aviv University's Blavatnik Center for Drug Discovery have launched a joint initiative combining Artificial Intelligence (AI)-driven computational chemistry with advanced experimental capabilities to accelerate small-molecule drug discovery.
Ofer Haviv | 08/07/2026 | By News Bureau | 100
Lishan Biotech secures exclusive worldwide rights to develop and commercialise BMC128, a Phase I microbiome-based immunotherapy candidate showing early promise in lung and renal cancers.
Ofer Haviv | 07/02/2026 | By News Bureau | 117
Evogene Appoints Dr Olga Nissan as VP for Business Development
Evogene has appointed Dr Olga Nissan as Vice President of Business Development, effective 1 January, 2026, bringing to the role a seasoned biotechnology and pharmaceutical leader with extensive experience spanning R&D, clinical development and business operations across pharma, diagnostics and agri-biotechnology sectors.
Ofer Haviv | 31/12/2025 | By News Bureau | 123
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy